Emerging role of sertindole in the management of schizophrenia

References

• AltamuraACBoboWVMeltzerHYFactors affecting outcome in schizophrenia and their relevance for psychopharmacological treatmentInt Clin Psychopharmcol2007225249267
   Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• SalimiKJarskogLFLiebermanJAAntipsychotic drugs for first-episode schizophrenia: a comparative reviewCNS Drugs2009231083785519739694
   PubMed Web of Science ®Google Scholar
• KasperSDo we need another atypical antipsychotic?Eur Neuropsychopharmacol200818Suppl 3S146S15218511242
   PubMed Web of Science ®Google Scholar
• CarpenterWTJrConleyRRBuchananRWBreierATammingaCAPatient response and resource management: another view of clozapine treatment of schizophreniaAm J Psychiatry199515268278327755110
   PubMed Web of Science ®Google Scholar
• KaneJMAntipsychotic medication in the treatment of schizophreniaIsr J Psychiatry Relat Sci199532130377542642
   PubMed Web of Science ®Google Scholar
• HaddadPMSharmaSGAdverse effects of atypical antipsychotics: differential risk and clinical implicationsCNS Drugs2007211191193617927296
   PubMed Web of Science ®Google Scholar
• WeidenPJEPS profiles: the atypical antipsychotics are not all the sameJ Psychiatr Pract2007131132417242588
   PubMedGoogle Scholar
• NasrallahHA review of the effect of atypical antipsychotics on weightPsychoneuroendocrinology200328Suppl 1S83S96
   PubMed Web of Science ®Google Scholar
• SuvisaariJMSaarniSIPeräläJMetabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population surveyJ Clin Psychiatry20076871045105517685741
   PubMed Web of Science ®Google Scholar
• LindenmayerJPCzoborPVolavkaJChanges in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychoticsAm J Psychiatry2003160229029612562575
   PubMed Web of Science ®Google Scholar
• MackinPBishopDWatkinsonHGallagherPFerrierINMetabolic disease and cardiovascular risk in people treated with antipsychotics in the communityBr J Psychiatry2007191232917602121
   PubMed Web of Science ®Google Scholar
• HaddadPMWieckAAntipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and managementDrugs200464202291231415456328
   PubMed Web of Science ®Google Scholar
• MeaneyAMSmithSHowesODO’BrienMMurrayRMO’KeaneVEffects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophreniaBr J Psychiatry200418450350815172944
   PubMed Web of Science ®Google Scholar
• KraepelinELectures on Clinical PsychiatryNew York, NYWilliam Wood & Co1904 Lecture III: Dementia praecox2129
   Google Scholar
• GreenMFKernRSBraffDLMintzJNeurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?Schizophr Bull20002611913610755673
   PubMed Web of Science ®Google Scholar
• WeinbergerDRGallhoferBCognitive function in schizophreniaInt Clin Psychopharmacol199712S29S369352344
   PubMed Web of Science ®Google Scholar
• TollefsonGDCognitive function in schizophrenic patientsJ Clin Psychiatry19965731398941169
   PubMed Web of Science ®Google Scholar
• BrewerWWoodSPhillipsLGeneralized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosisSchizophr Bull20063253855516782759
   PubMed Web of Science ®Google Scholar
• AddingtonJAddingtonDNeurocognitive and social functioning in schizophreniaSchizophr Bull19992517318210098920
   PubMed Web of Science ®Google Scholar
• GreenMFWhat are the functional consequences of neurocognitive deficits in schizophreniaAm J Psychiatry19961533213308610818
   PubMed Web of Science ®Google Scholar
• HarveyPDParrellaMWhiteLMohsRCDavidsonMDavisKLConvergence of cognitive and adaptive decline in late-life schizophreniaSchizophr Res19993577849988843
   PubMed Web of Science ®Google Scholar
• MortimerAMCognitive function in schizophrenia – Do neuroleptics make a differencePharmacol Biochem Behav1997567897959130306
   PubMed Web of Science ®Google Scholar
• CleghornJMKaplanRDSzechtmanBSzechtmanHBrownGMNeuroleptic drug effects on cognitive function in schizophreniaSchizophr Res199032112191980613
   PubMed Web of Science ®Google Scholar
• CutmoreTRHBeningerRJDo neuroleptics impair learning in schizophrenic patientsSchizophr Res199031731861980612
   PubMed Web of Science ®Google Scholar
• FittonAHeelRCClozapine. A review of its pharmacological properties, and therapeutic use in schizophreniaDrugs1990407227472292234
   PubMed Web of Science ®Google Scholar
• FultonBGoaKLOlanzapine, a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychosesDrugs1997532812989028746
   PubMed Web of Science ®Google Scholar
• KaneJMTammingaCASertindole (serdolect): preclinical and clinical findings of a new atypical antipsychoticExp Opin Invest Drugs1997617291741
   PubMedGoogle Scholar
• AzorinJMStrubNLoftHA double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophreniaInt J Psychopharmacol2006214956
   PubMed Web of Science ®Google Scholar
• MeltzerHYMcGurkSRThe effects of clozapine, risperidone, and olanzapine on cognitive function in schizophreniaSchizophr Bull19992523325510416729
   PubMed Web of Science ®Google Scholar
• KeefeRSEBilderRMDavisSMNeurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trialArch Gen Psychiatry20076463364717548746
   PubMed Web of Science ®Google Scholar
• HoffALFaustmanWOWienekeMThe effect of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatientsNeuropsychopharmacology1996153613698887990
   PubMed Web of Science ®Google Scholar
• GoldbergTEGreenbergRDGriffinSJThe effect of clozapine on cognition and psychiatric symptoms in patients with schizophreniaBr J Psychiatry199316243488425138
   PubMed Web of Science ®Google Scholar
• WuEQBirnbaumHGShiLThe economic burden of schizophrenia in the United States in 2002J Clin Psychiatry20056691122112916187769
   PubMed Web of Science ®Google Scholar
• PerquinLSteinertTA review of the efficacy, tolerability and safety of sertindole in clinical trialsCNS Drugs200418Suppl 2S19S30
   PubMed Web of Science ®Google Scholar
• van KammenDPMcEvoyJPTargumSDKardatzkeDSebreeTBA randomized, controlled, dose-ranging trial of sertindole in patients with schizophreniaPsychopharmacology (Berl)19961241681758935813
   PubMed Web of Science ®Google Scholar
• FardeLNordströmALWieselFAPauliSHalldinCSedvallGPositron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effectsArch Gen Psychiatry19924975385441352677
   PubMed Web of Science ®Google Scholar
• KapurSBarsoumSCSeemanPDopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQNeuropsychopharmacology200023559559811027926
   PubMed Web of Science ®Google Scholar
• KasperSTauscherJKüfferleBSertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol – a 123I-IBZM SPECT studyPsychopharmacology (Berl)199813643673739600582
   PubMed Web of Science ®Google Scholar
• MooreNHigher cardiovascular mortality with sertindole in ADROIT: a signal not confirmedInt J Psychiatry Clin Pract20026Suppl 1S3S9
   Web of Science ®Google Scholar
• MooreNHallGSturkenboomMMannRLagnaouiRBegaudBBiases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindolePharmacoepidemiol Drug Saf200312427128112812006
   PubMed Web of Science ®Google Scholar
• PezawasLQuinerSMoertlDEfficacy, cardiac safety, and tolerability of sertindole: a drug surveillanceInt Clin Psychopharmacol200015420721410954060
   PubMed Web of Science ®Google Scholar
• WehnertAThe European Post-marketing Observational Serdolect® (EPOS) project: increasing our understanding of schizophrenia therapyInt Clin Psychopharmacol199813Suppl 3S27S309690967
   PubMed Web of Science ®Google Scholar
• WiltonLVHeeleyELPickeringRMShakirSAComparative study of mortality rates and cardiac dysrythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapineJ Psychopharmacol20011512012611448085
   PubMed Web of Science ®Google Scholar
• HyttelJArntJCostallBPharmacological profile of the atypical neuroleptic sertindoleClin Neuropharmacol199215Suppl 1 Pt A267A268A
   Google Scholar
• BundgaardCLarsenFKreilgaardMBrennumLTOlsenCKPharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance responseBiopharm Drug Dispos200930420922019475539
   PubMed Web of Science ®Google Scholar
• WatanabeMHaginoYThe atypical antipsychotic sertindole enhances efflux of dopamine and its metabolites in the rat cortex and striatumEur J Pharmacol19993671192310082260
   PubMed Web of Science ®Google Scholar
• WarnerJPBarnesTRHenryJAElectrocardiographic changes in patients receiving neuroleptic medicationActa Psychiatr Scand19969343113138712033
   PubMed Web of Science ®Google Scholar
• ShenWWThe metabolism of atypical antipsychotic drugs: an updateAnn Clin Psychiatry199911314515810482125
   PubMedGoogle Scholar
• OzekiYFujiiKKurimotoNQTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201034240140520079791
   PubMed Web of Science ®Google Scholar
• MauriMCVolonteriLSColasantiAFiorentiniADe GaspariIFBareggiSRClinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical responseClin Pharmacokinet200746535938817465637
   PubMed Web of Science ®Google Scholar
• DavisASThe pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methodsHum Exp Toxicol199817126776809988372
   PubMed Web of Science ®Google Scholar
• DriciMDWangWXLiuXKWoosleyRLFlockhartDAProlongation of QT interval in isolated feline hearts by antipsychotic drugsJ Clin Psychopharmacol19981864774819864081
   PubMed Web of Science ®Google Scholar
• HaleASA review of the safety and tolerability of sertindoleInt Clin Psychopharmacol199813Suppl 3S65S709690973
   PubMed Web of Science ®Google Scholar
• AgelinkMWMajewskiTWurthmannCEffects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapineJ Clin Psychopharmacol200121181311199953
   PubMed Web of Science ®Google Scholar
• GuryCCanceilOIariaPAntipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmiaEncephale2000266627211217540
   PubMed Web of Science ®Google Scholar
• ThomsenMBVoldersPGStenglMElectrophysiological safety of sertindole in dogs with normal and remodeled heartsJ Pharmacol Exp Ther2003307277678412966159
   PubMed Web of Science ®Google Scholar
• EckardtLBreithardtGHaverkampWElectrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongationJ Pharmacol Exp Ther20023001647111752098
   PubMed Web of Science ®Google Scholar
• TitierKGirodetPOVerdouxHAtypical antipsychotics: from potassium channels to torsade de pointes and sudden deathDrug Saf2005281355115649104
   PubMed Web of Science ®Google Scholar
• TitierKCanalMDéridetEDetermination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practiceToxicol Appl Pharmacol20041991526015289090
   PubMed Web of Science ®Google Scholar
• BaptistaTKinNMBeaulieuSde BaptistaEAObesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectivesPharmacopsychiatry200235620521912518268
   PubMed Web of Science ®Google Scholar
• SpinaEde LeonJMetabolic drug interactions with newer antipsychotics: a comparative reviewBasic Clin Pharmacol Toxicol2007100142217214606
   PubMed Web of Science ®Google Scholar
• TaylorDPharmacokinetic interactions involving clozapineBr J Psychiatry19971711091129337943
   PubMed Web of Science ®Google Scholar
• BhanaNFosterRHOlneyRPloskerGLOlanzapine: an updated review of its use in the management of schizophreniaDrugs200161111116111217867
   PubMed Web of Science ®Google Scholar
• SakamotoKNakamuraYAikohSMetabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolismXenobiotica19952512132713438719908
   PubMed Web of Science ®Google Scholar
• DanielWAKotMWojcikowskiJInfluence of classic and atypical neuroleptics on caffeine oxidation in rat liver microsomesPol J Pharmacol20035561055106114730101
   PubMedGoogle Scholar
• WongSLLinnenPMackRGrannemanGREffects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteersBiopharm Drug Dispos19971865335419267685
   PubMed Web of Science ®Google Scholar
• HaduchAWojcikowskiJDanielWADirect effects of neuroleptics on the activity of CYP2A in the liver of ratsPharmacol Rep200557686787116382210
   PubMed Web of Science ®Google Scholar
• EreshefskyLPharmacokinetics and drug interactions: update for new antipsychoticsJ Clin Psychiatry199657Suppl 11S12S25
   Google Scholar
• HaduchAOgorkaTBoksaJDanielWAInteractions between neuroleptics and CYP2C6 in rat liver – in vitro and ex vivo studyPharmacol Rep200557687287716382211
   PubMed Web of Science ®Google Scholar
• WongSLLockeCStaserJGrannemanGRLack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteersPsychopharmacology (Berl)199813532362419498726
   PubMed Web of Science ®Google Scholar
• WongSLGrannemanGRModeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studiesJ Pharm Sci199887121629163110189278
   PubMed Web of Science ®Google Scholar
• WongSLMenacherrySMulfordDSchmitzPJLockeCGrannemanGRPharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal functionEur J Clin Pharmacol19975232232279218930
   PubMed Web of Science ®Google Scholar
• WongSLCaoGMackRJGrannemanGRThe effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteersJ Clin Pharmacol19973711105610619505999
   PubMed Web of Science ®Google Scholar
• ZimbroffDLKaneJMTammingaCAControlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study GroupAm J Psychiatry199715467827919167505
   PubMed Web of Science ®Google Scholar
• DanielDGWozniakPMackRJMcCarthyBGfor the Sertindole Study GroupLong-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophreniaPsychopharmacol Bull19983461699564200
   PubMed Web of Science ®Google Scholar
• HaleAAzorinJMKasperSSertindole improves both the positive and negative symptomcs of schizophrenia: resuts of a Phase III trialInt J Psychiatry Clin Pract2000415562
   Web of Science ®Google Scholar
• KaneJMPotkinSGDanielDGBuckleyPA double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophreniaJ Clin Psychiatry2010In press
   Web of Science ®Google Scholar
• KomossaKRummel-KlugeCHungerHSertindole versus other atypical antipsychotics for schizophreniaCochrane Database Syst Rev2009152CD00675219370652
   PubMed Web of Science ®Google Scholar
• SteinertTHaugerBEckardtJSchmidPClinical observations of sertindole in 53 hospitalised patients with psychotic disordersClin Drug Investig20052517983
   Web of Science ®Google Scholar
• TammingaCAMackRAGrannemanGRSilberCJKashkinKBSertindole in the treatment of psychosis in schizophrenia: efficacy and safetyInt Clin Psychopharmacol199712Suppl 1S29S359179641
   PubMed Web of Science ®Google Scholar
• MooreNLagnaouiRToumiMBegaudBSuicide and sudden death during treatment with atypical neuroleptics: a comparison of sertindole, olanzapine, and risperidoneSchizophr Res199936356357
   Web of Science ®Google Scholar
• SturkenboomMCJMPicelliGMooreNMortality during use of sertindole and other antipsychotics in the Netherlands and Belgium [abstract 273]Pharmacoepidemiol Drug Safety200110S1S164
   PubMedGoogle Scholar
• MurdochDKeatingGMSertindole: a review of its use in schizophreniaCNS Drugs200620323325516529528
   PubMed Web of Science ®Google Scholar
• PeuskensJTanghojPMittouxAOutcome of the Sertindole Cohort Prospective (SCoP) study: all-cause mortalityPoster presented at: the 15th Winter Workshop in Psychoses2009 Nov 15–18Barcelona, Spain
   Google Scholar
• LançonCToumiMSapinCHansenKThe Sertindole Safety Survey: a retrospective analysis under a named patient use programme in EuropeBMC Psychiatry 200885718638382
   PubMed Web of Science ®Google Scholar
• LindströmEFardeLEberhardJHaverkampWQTc interval prolongation and antipsychotic drug treatments: focus on sertindoleInt J Neuropsychopharmacol20058461562915963244
   PubMed Web of Science ®Google Scholar
• AtmacaMYavuzkirMMermiOTopuzMKanmazETezcanEEffect of sertindole on QTc interval in patients with schizophreniaNeurosci Lett200844211318639380
   PubMed Web of Science ®Google Scholar
• HarriganEPMiceliJJAnzianoRA randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibitionJ Clin Psychopharmacol200424626914709949
   PubMed Web of Science ®Google Scholar
• RedfernWSCarlssonLDavisASRelationships between preclinical cardiac electrophysiology, clinical QT interval prolongation, and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug developmentCardiovasc Res200358324512667944
   PubMed Web of Science ®Google Scholar
• TaylorDMAntipsychotics and QT prolongationActa Psychiatr Scand2003107859512534433
   PubMed Web of Science ®Google Scholar
• NielsenJGraffCHardahlTSertindole causes distinct electrocardiographic T-wave morphology changesEur Neuropsychopharmacol2009191070270719457646
   PubMed Web of Science ®Google Scholar
• PerquinLTreatment with the new antipsychotic sertindole for late-occurring undesirable movement effectsInt Clin Psychopharmacol200520633533816192844
   PubMed Web of Science ®Google Scholar
• SacchettiEValsecchiPQuetiapine, olanzapine, and clozapine in the treatment of tardive dyskinesiaJ Clin Psychopharmacol200318357359
   Google Scholar
• NewcomerJWMetabolic syndrome and mental illnessAm J Manag Care200713Suppl 7S170S17718041878
   PubMed Web of Science ®Google Scholar
• De HertMMittouxAHeYPeuskensJMetabolic parameters in the short- and long-term treatment of schizophrenia with sertindole and risperidonePoster presented at: the 15th Winter Workshop in Psychoses2009 Nov 15–18Barcelona, Spain
   Google Scholar
• LohCLeckbandSGMeyerJMTurnerERisperidone-induced retrograde ejaculation: case report and review of the literatureInt Clin Psychopharmacol200419211111215076020
   PubMed Web of Science ®Google Scholar
• SmithPJTalbertRLSexual dysfunction with antihypertensive and antipsychotic agentsClin Pharm1986553733842872991
   PubMedGoogle Scholar
• SkarsfeldtTDifferential effect of antipsychotics on place navigation of rats in the Morris water mazePsychopharmacology (Berl)19961241261338935807
   PubMed Web of Science ®Google Scholar
• DidriksenMKreilgaardMArntJSertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatmentEur J Pharmacol20065421310811516797002
   PubMed Web of Science ®Google Scholar
• DidriksenMSkarsfeldtTArntJReversal of PCP-induced learning and memory deficits in the Morris’ water maze by sertindole and other antipsychoticsPsychopharmacology (Berl)2007193222523317406859
   PubMed Web of Science ®Google Scholar
• GoetghebeurPDiasRComparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat – a back translational studyPsychopharmacology (Berl)20092021328729319002439
   PubMed Web of Science ®Google Scholar
• RodeferJSNguyenTNKarlssonJJArntJReversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychoticsNeuropsychopharmacology200833112657266618094666
   PubMed Web of Science ®Google Scholar
• BurnhamKEBaxterMGBaintonJRActivation of 5-HT6 receptors facilitates attentional set shiftingPsychopharmacology2010208132119902184
   PubMed Web of Science ®Google Scholar
• HatcherPDBrownVJTaitDS5-HT6 receptor antagonists improve performance in an attentional set-shifting task in ratsPsychopharmacology (Berl)200518125325915846482
   PubMed Web of Science ®Google Scholar
• MitchellESNeumaierJF5-HT6 receptors: a novel target for cognitive enhancementPharmacol Ther200510832033316005519
   PubMed Web of Science ®Google Scholar
• UptonNChuangTTHunterAJVirleyDJ5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s diseaseNeurotherapeutics2008545846918625457
   PubMed Web of Science ®Google Scholar
• GallhoferBJaansonPMittouxATanghøjPLisSKriegerSCourse of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidolPharmacopsychiatry200740627528618030652
   PubMed Web of Science ®Google Scholar
• BuchsbaumMSHaznedarMNewmarkREFDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophreniaSchizophr Res20091141316117119683417
   PubMed Web of Science ®Google Scholar
• LacroixLPDawsonLAHaganJJHeidbrederCA5HT-6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortexSynapse20045115816414618683
   PubMed Web of Science ®Google Scholar
• MeltzerHYBaldessariniRJReducing the risk for suicide in schizophrenia and affective disordersJ Clin Psychiatry2003641122112914628990
   PubMed Web of Science ®Google Scholar
• MeltzerHYAlphsLGreenAIClozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)Arch Gen Psychiatry2003601829112511175
   PubMed Web of Science ®Google Scholar
• CrocqMAMittouxATanghojPNaberDSuicide in a prospective cohort of patients with schizophrenia treated with sertindole or risperidonePoster presented at: the 15th Winter Workshop in Psychoses2009 Nov 15–18Barcelona, Spain
   Google Scholar
• LindenmayerJPLiu-SeifertHKulkarniPMMedication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJ Clin Psychiatry200970799099619497244
   PubMed Web of Science ®Google Scholar
• AzorinJMMurteiraSHansenKToumiMEvaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysisBMC Psychiatry 200881618366634
   PubMedGoogle Scholar
• SchuckPvan den AmeeleHJaansonPRyckmansVHawleyCCase histories illustrating the utility of sertindole in clinical practiceCNS Drugs200418Suppl 2S31S40
   Web of Science ®Google Scholar
• LublinHEberhardJLevanderSCurrent therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychoticsInt Clin Psychopharmacol200520418319815933479
   PubMed Web of Science ®Google Scholar
• PeuskensJIntroduction to sertindole in clinical practiceCNS Drugs200418Suppl 21415461311
   PubMed Web of Science ®Google Scholar
• RodeferJSThe effects of antipsychotics on reversing PCP-induced deficits in a rodent attentional set-shifting taskSchizophr Res200681S130S131
   Web of Science ®Google Scholar
• HochmanMMcCormickDCharacteristics of published comparative effectiveness studies of medicationsJAMA20103031095195820215609
   PubMed Web of Science ®Google Scholar